{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T18:58:49Z","timestamp":1783796329184,"version":"3.55.0"},"reference-count":47,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>The in vitro interactions of isavuconazole in combination with colistin were evaluated against 55 clinical Aspergillus species isolates belonging to the five most important species (Aspergillus flavus, Aspergillus fumigatus, Aspergillus nidulans, Aspergillus niger, and Aspergillus terreus) responsible for human aspergillosis by a microdilution checkerboard technique based on the European Committee on Antimicrobial Susceptibility Testing (EUCAST) reference method for antifungal susceptibility testing. Selected isolates (A. nidulans, n = 10; A. niger, n = 15) were additionally evaluated by an agar diffusion assay using isavuconazole gradient concentration strips with or without colistin incorporated Roswell Parc Memorial Institute (RPMI) agar. Interpretation of the checkerboard results was done by the fractional inhibitory concentration index. Using the checkerboard method, combination isavuconazole\u2013colistin was synergistic for 100% of the 15 A. nidulans isolates and for 60% of the 20 A. niger isolates. No interactions were found for any of the other isolates. By agar diffusion assay, minimal inhibitory concentrations (MICs) in combination decreased compared to isavuconazole alone for 92% of the isolates. No interactions were found for any A. nidulans isolates, but synergy was observed for 40% of the A. niger isolates. A poor essential agreement of EUCAST and gradient concentration strip MICs at \u00b1 2 log2 dilutions with 0% was obtained. Antagonistic interactions were never observed regardless of the technique used.<\/jats:p>","DOI":"10.3390\/microorganisms8091447","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T08:18:01Z","timestamp":1600676281000},"page":"1447","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Colistin and Isavuconazole Interact Synergistically In Vitro against Aspergillus nidulans and Aspergillus niger"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0383-1865","authenticated-orcid":false,"given":"Patrick","family":"Schwarz","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Respiratory and Critical Care Medicine, University Hospital Marburg, Baldingerstra\u00dfe, D-35043 Marburg, Germany"},{"name":"Center for Invasive Mycoses and Antifungals, School of Medicine, Philipps University Marburg, D-35037 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Djenontin","sequence":"additional","affiliation":[{"name":"Dynamyc Research Group (EA 7380), Facult\u00e9 de M\u00e9decine de Cr\u00e9teil, Universit\u00e9 Paris-Est-Cr\u00e9teil-Val-de-Marne, F-94010 Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2817-3830","authenticated-orcid":false,"given":"Eric","family":"Dannaoui","sequence":"additional","affiliation":[{"name":"Dynamyc Research Group (EA 7380), Facult\u00e9 de M\u00e9decine de Cr\u00e9teil, Universit\u00e9 Paris-Est-Cr\u00e9teil-Val-de-Marne, F-94010 Cr\u00e9teil, France"},{"name":"Service de Microbiologie, Unit\u00e9 de Parasitologie-Mycologie, H\u00f4pital Europ\u00e9en Georges-Pompidou, F-75015 Paris, France"},{"name":"Facult\u00e9 de M\u00e9decine, Universit\u00e9 de Paris, F-75006 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Latg\u00e9, J.P., and Chamilos, G. (2019). Aspergillus fumigatus and aspergillosis in 2019. Clin. Microbiol. Rev., 33.","DOI":"10.1128\/CMR.00140-18"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMra0808853","article-title":"Aspergillosis","volume":"360","author":"Segal","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: Rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","article-title":"Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: A retrospective cohort study","volume":"6","author":"Schauwvlieghe","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1164\/rccm.202004-1038LE","article-title":"COVID-19-associated Pulmonary Aspergillosis","volume":"202","author":"Rijpstra","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1086\/323900","article-title":"The impact of culture isolation of Aspergillus species: A hospital-based survey of aspergillosis","volume":"33","author":"Perfect","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1099\/mic.0.2007\/007641-0","article-title":"Aspergillus flavus: Human pathogen, allergen and mycotoxin producer","volume":"153","author":"Hedayati","year":"2007","journal-title":"Microbiology (Reading)"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11046-014-9811-z","article-title":"Treatment of infections by cryptic Aspergillus species","volume":"178","author":"Nedel","year":"2014","journal-title":"Mycopathologia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/EC.4.3.625-632.2005","article-title":"Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus","volume":"4","author":"Balajee","year":"2005","journal-title":"Eukaryot. Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11046-014-9775-z","article-title":"Antifungal susceptibility profile of cryptic species of Aspergillus","volume":"178","year":"2014","journal-title":"Mycopathologia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QCO.0000000000000005","article-title":"Azole resistance in Aspergillus fumigatus: A growing public health concern","volume":"26","author":"Vermeulen","year":"2013","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/infdis\/jis442","article-title":"In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a Cyp51a M217I alteration","volume":"206","author":"Arendrup","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Imbert, S., Normand, A.C., Ranque, S., Costa, J.M., Guitard, J., Accoceberry, I., Bonnal, C., Fekkar, A., Bourgeois, N., and Houze, S. (2018). Species identification and in vitro antifungal susceptibility of Aspergillus terreus species complex clinical isolates from a French multicenter study. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.02315-17"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Rudramurthy, S.M., Paul, R.A., Chakrabarti, A., Mouton, J.W., and Meis, J.F. (2019). Invasive aspergillosis by Aspergillus flavus: Epidemiology, diagnosis, antifungal resistance, and management. J. Fungi, 5.","DOI":"10.3390\/jof5030055"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus","volume":"21","author":"Arendrup","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S1473-3099(09)70265-8","article-title":"Azole resistance in Aspergillus fumigatus: A side-effect of environmental fungicide use?","volume":"9","author":"Verweij","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/21505594.2016.1196300","article-title":"Combinatorial strategies for combating invasive fungal infections","volume":"8","author":"Spitzer","year":"2017","journal-title":"Virulence"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1592\/phco.30.12.1279","article-title":"Resurgence of colistin: A review of resistance, toxicity, pharmacodynamics, and dosing","volume":"30","author":"Lim","year":"2010","journal-title":"Pharmacotherapy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13756-019-0521-7","article-title":"In vitro polymyxin activity against clinical multidrug-resistant fungi","volume":"8","author":"Yousfi","year":"2019","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1128\/AAC.00956-09","article-title":"Antifungal activity of colistin against Mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection","volume":"54","author":"Lewis","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","unstructured":"Schwarz, P., Bidaud, A.L., and Dannaoui, E. In vitro synergy of isavuconazole in combination with colistin against Candida auris, (unpublished work; manuscript in preparation)."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"105901","DOI":"10.1016\/j.ijantimicag.2020.105901","article-title":"Colistin interacts synergistically with echinocandins against Candida auris","volume":"55","author":"Bidaud","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1128\/JCM.39.2.478-484.2001","article-title":"Analysis of growth characteristics of filamentous fungi in different nutrient media","volume":"39","author":"Meletiadis","year":"2001","journal-title":"J. Clin. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_29","first-page":"143","article-title":"Antifungal combinations","volume":"118","author":"Vitale","year":"2005","journal-title":"Methods Mol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S436","DOI":"10.1093\/infdis\/jix210","article-title":"Azole-resistant aspergillosis: Epidemiology, molecular mechanisms, and treatment","volume":"216","author":"Chowdhary","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd.2017.46","article-title":"The antifungal pipeline: A reality check","volume":"16","author":"Perfect","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1128\/AAC.01111-13","article-title":"Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method","volume":"57","author":"Howard","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1139\/w99-075","article-title":"Use of spectrophotometric reading for in vitro antifungal susceptibility testing of Aspergillus spp.","volume":"45","author":"Dannaoui","year":"1999","journal-title":"Can. J. Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cmi.2016.10.017","article-title":"Spectrophotometric reading of EUCAST antifungal susceptibility testing of Aspergillus fumigatus","volume":"23","author":"Meletiadis","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Schwarz, P., and Dannaoui, E. (2020). In vitro interaction between isavuconazole and tacrolimus, cyclosporin, A.; or sirolimus against Aspergillus Species. J. Fungi, 6.","DOI":"10.3390\/jof6030103"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1128\/AAC.01512-07","article-title":"In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species","volume":"52","author":"Guinea","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Carrara, B., Richards, R., Imbert, S., Morio, F., Sasso, M., Zahr, N., Normand, A.C., Le Pape, P., Lachaud, L., and Ranque, S. (2020). Species distribution and comparison between EUCAST and gradient concentration strips methods for antifungal susceptibility testing of 112 Aspergillus section Nigri isolates. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.02510-19"},{"key":"ref_38","first-page":"1439","article-title":"Unveiling the synergistic interaction between liposomal amphotericin B and colistin","volume":"7","author":"Ricardo","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s10096-013-1850-8","article-title":"Enhanced efficacy of synergistic combinations of antimicrobial peptides with caspofungin versus Candida albicans in insect and murine models of systemic infection","volume":"32","author":"MacCallum","year":"2013","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/jac\/dks538","article-title":"Synergy of the antibiotic colistin with echinocandin antifungals in Candida species","volume":"68","author":"Zeidler","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/myc.12022","article-title":"In vitro activity of colistin as single agent and in combination with antifungals against filamentous fungi occurring in patients with cystic fibrosis","volume":"56","author":"Schemuth","year":"2013","journal-title":"Mycoses"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0966-842X(03)00117-3","article-title":"Antifungal agents: Mechanisms of action","volume":"11","author":"Odds","year":"2003","journal-title":"Trends Microbiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/00912700122010537","article-title":"The pharmacokinetics of colistin in patients with cystic fibrosis","volume":"41","author":"Reed","year":"2001","journal-title":"J. Clin. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2110-5820-1-14","article-title":"Renal and neurological side effects of colistin in critically ill patients","volume":"1","author":"Spapen","year":"2011","journal-title":"Ann. Intensive Care"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"55","author":"Garonzik","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1128\/AAC.00990-07","article-title":"Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: Correlation with outcome in solid organ transplant recipients with cryptococcosis","volume":"52","author":"Kontoyiannis","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/8\/9\/1447\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:12:06Z","timestamp":1760177526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/8\/9\/1447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["microorganisms8091447"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms8091447","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]}}}